-0.70%
-24.30%
49.89%
86.01%
-44.99%
-89.79%
-93.89%
AI Spotlight on SLGL
Company Description
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel.The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions.It is also involved in the development of generic topical dermatological drug products.
The company has collaboration with Perrigo.Sol-Gel Technologies Ltd.was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Market Data
| Last Price | 0.76 |
| Change Percentage | -0.70% |
| Open | 0.8 |
| Previous Close | 0.77 |
| Market Cap ( Millions) | 21 |
| Volume | 63988 |
| Year High | 1.65 |
| Year Low | 0.33 |
| M A 50 | 0.79 |
| M A 200 | 0.72 |
Financial Ratios
| FCF Yield | 0.00% |
| Dividend Yield | 0.00% |
| ROE | -27.17% |
| Debt / Equity | 3.76% |
| Net Debt / EBIDTA | 112.17% |
| Price To Book | 0.61 |
| Price Earnings Ratio | -2.23 |
| Price To FCF | 0 |
| Price To sales | 1.82 |
| EV / EBITDA | -0.85 |
News
- Nov -20 - SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know
- Nov -15 - Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue Estimates
- Nov -15 - Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
- Sep -17 - SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
- Aug -27 - All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy
- Aug -16 - Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates
- Aug -16 - Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
- Jul -15 - Sol-Gel Technologies Announces Management Realignment
- May -20 - Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
- May -20 - Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- May -16 - Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
- Apr -01 - Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
- Mar -13 - Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
- Nov -30 - Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
- Nov -28 - Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
- Nov -09 - Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Oct -30 - 3 Generic Drug Stocks to Watch Amid Improving Market Prospects
- Oct -27 - Is Phillips 66 (PSX) Stock Undervalued Right Now?
- Aug -30 - Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- Aug -10 - Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Topical Dermatological Drug
Expected Growth : 8.97 %
What the company do ?
Epsolay is a topical dermatological drug from Sol-Gel Technologies Ltd. for treating papulopustular rosacea, characterized by its unique gel formulation and proprietary nanotechnology.
Why we expect these perspectives ?
Sol-Gel Technologies Ltd.'s topical dermatological drug growth is driven by increasing prevalence of skin diseases, rising demand for non-invasive treatments, and growing awareness of aesthetic appeal. Additionally, the company's proprietary technology and strong pipeline of products contribute to its growth, along with strategic partnerships and expanding distribution channels.
Sol-Gel Technologies Ltd. Products
| Product Range | What is it ? |
|---|---|
| BenzaClin | Topical cream for the treatment of acne, containing benzoyl peroxide and clindamycin |
| Epsolay | Topical cream for the treatment of papulopustular rosacea, containing benzoyl peroxide |
| TWYNEO | Topical cream for the treatment of acne, containing benzoyl peroxide and tretinoin |
| Customized Topical Products | Sol-Gel's proprietary technology allows for the development of customized topical products for pharmaceutical and cosmetic companies |
Sol-Gel Technologies Ltd.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Sol-Gel Technologies Ltd. is medium due to the availability of alternative technologies and materials in the market.
Bargaining Power Of Customers
The bargaining power of customers for Sol-Gel Technologies Ltd. is low due to the company's strong brand reputation and customer loyalty.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Sol-Gel Technologies Ltd. is medium due to the company's dependence on a few key suppliers for raw materials.
Threat Of New Entrants
The threat of new entrants for Sol-Gel Technologies Ltd. is high due to the relatively low barriers to entry in the industry and the attractiveness of the market.
Intensity Of Rivalry
The intensity of rivalry for Sol-Gel Technologies Ltd. is high due to the presence of several established competitors in the market and the high stakes of competition.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 4.10% |
| Debt Cost | 3.95% |
| Equity Weight | 95.90% |
| Equity Cost | 10.84% |
| WACC | 10.55% |
| Leverage | 4.28% |
Sol-Gel Technologies Ltd. : Quality Control
Sol-Gel Technologies Ltd. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OXB.L | Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform … |
| EVGN | Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through … |
| AFMD | Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has … |
| MLEC | Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and … |
| EXAI | Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Oxford Biomedica
A-Score
1-Year Total Return ->
🥈
Moolec Science
A-Score
1-Year Total Return ->
🥉
Evogene
A-Score
1-Year Total Return ->
4
Sol-Gel Technologies
A-Score
1-Year Total Return ->
5
Exscientia
A-Score
1-Year Total Return ->
6
